# A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

> **NCT04225923** · PHASE2 · COMPLETED · sponsor: **Nobelpharma** · enrollment: 87 (actual)

## Conditions studied

- Cytomegalovirus Disease

## Interventions

- **DRUG:** NPC-21 Low dose
- **DRUG:** NPC-21 High dose
- **DRUG:** NPC-21 Placebo

## Key facts

- **NCT ID:** NCT04225923
- **Lead sponsor:** Nobelpharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2022-11-02
- **Final completion:** 2023-02-08
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225923, "A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04225923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*